Journal of Thyroid Disorders & Therapy
Open Access

Department of Diagnostic Pathology and Cytology, Kuma Hospital, Kobe, Japan

Biography

 Dr. Mitsuyoshi Hirokawa currently working at Kuma Hospitals  in the department of Diagnostic pathology and Cytology. His top areas of expertise are Follicular Thyroid Cancer, Thyroid Cancer, Papillary Thyroid Cancer, and Anaplastic Thyroid Cancer. He is having morethan 450 publictions in reputed journals

Publications

• Original Research Article   
  Factors Influencing the Chemo-Sensitivity of Weekly Paclitaxel for Anaplastic Thyroid Cancer: A Clinico-Pathologic Analysis of Cases Enrolled in a Clinical Trial
  Author(s): Naoyoshi Onoda*, Mitsuyoshi Hirokawa, Kennichi Kakudo, Atsuhiko Sakamoto, Kiminori Sugino, Noriaki Nakashima, Nobuyasu Suganuma, Shinichi Suzuki, Ken-ichi Ito and Iwao Sugitani
  
  This study was conducted to identify the clinico-pathologic factors influencing the response to weekly paclitaxel treatment for Anaplastic Thyroid Cancer (ATC), a rare refractory disease. We investigated clinico-pathological factors as well as the expressions of Ki67, p53, MAD2, TLE3, ALDH1, β-tubulin, E-cadherin and vimentin among the subjects enrolled in a recent nationwide clinical trial of 56 patients with ATC in Japan. We compared the factors of eight responders and eight non-responders. The responders survived significantly longer than the non-responders (median 11.6 vs. 3.6 months, p=0.039). No significant between-group difference was found in histological subtype, TNM classification, or the expression of Ki67, p53, MAD2, TLE3, ALDH1, β-tubulin, E-cadherin or vimentin. When the patients' Prognostic Index (PI) was determined with the sum of four clinical factors, i.. View More»
  

  Abstract PDF